Sequestration of anti-Cra in the placenta: Serologic demonstration by placental elution

Transfusion

Volumn 45, Issue 8, 2005, Pages 1327-1330

  Weber, Shanasey L ^a   Bryant, Barbara J ^a,b   Indrikovs, Alexander J ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIBODY; BLOOD GROUP ANTIGEN; CROMER (A) ANTIBODY; CROMER (A) ANTIGEN; UNCLASSIFIED DRUG; ALLOANTIBODY; DECAY ACCELERATING FACTOR;

ADULT; AFRICAN AMERICAN; ANAMNESIS; ANTIBODY TITER; ARTICLE; BED REST; CASE REPORT; CONTROLLED STUDY; COOMBS TEST; DELIVERY; ELUTION; FEMALE; HUMAN; MATERNAL PLASMA; NEWBORN HEMOLYTIC DISEASE; PLACENTA; PREGNANCY; PREMATURE LABOR; PRENATAL CARE; SEROLOGY; UMBILICAL CORD BLOOD; BLOOD; IMMUNOLOGY;

ADULT; ANTIGENS, CD55; BLOOD GROUP ANTIGENS; FEMALE; HUMANS; ISOANTIBODIES; PLACENTA; PREGNANCY;

EID: 23844436991     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.00205.x     Document Type: Article

References (14)

1. Telen MJ, Hall SE, Green AM, et al. Identification of human erythrocyte blood group antigens on decay accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med 1988;167:1993-8.
2. Parsons SF, Spring FA, Merry AH, et al. Evidence that Cromer-related blood group antigens are carried on decay accelerating factor (DAF) suggests that the Inab phenotype is a novel form of DAF deficiency [abstract]. Proceedings of the XXth Congress of the International Society of Blood Transfusion. Manchester: British Blood Transfusion Society; 1988. p. 116.
3. Spring FA, Judson PA, Daniels GL, et al. A human cell-surface glycoprotein that carries Cromer-related blood group antigens on erythrocytes and is also expressed on leukocytes and platelets. Immunology 1987;62:307-13.
4. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay accelerating factor (DAF) into their membranes. J Exp Med 1984;160:1558.
5. Holmes CH, Simpson KL, Wainright SD, et al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol 1990;144:3099-105.
6. Holmes CH, Simpson KL, Okada H, et al. Complement regulatory proteins at the fetomaternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol 1992;22: 1579-85.
7. a epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology. Blood 1994;84:3205-11.
8. Issit PD, Anstee DJ. Applied blood group serology. 4th ed. Durham (NC): Montgomery Scientific Publications; 1994.
9. Storry JR, Reid ME. The Cromer blood group system: a review. Immunohematology 2002;18:95-103.
10. a. 18th Annual Meeting Program. Chicago: American Association of Blood Banks; 1965. p. 59.
11. a, another high frequency blood group factor [abstract]. Transfusion 1975;15:522.
12. Sacks DA, Garratty G. Isoimmunization to Cromer antigen in pregnancy. Am J Obstet Gynecol 1989;161:928-9.
13. a in pregnancy. Immunohematology 1995;11:14-7.
14. Reid ME, Chandrasekaran V, Sausais L, et al. Disappearance of antibodies to Cromer blood group system antigens during mid pregnancy. Vox Sang 1996;71:48-50.